Notice of Preliminary Results

Tissue Regenix Group plc

Notice of Preliminary Results

YORK, 12 May 2014 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, announces that it will publish its unaudited preliminary results for the year ended 31 January, 2014, on Monday 19 May, 2014.

ENDS

For Further Information

Tissue Regenix Group Plc: +44 (0)1904 43 5176

Antony Odell, Chief Executive Officer

Ian Jefferson, Chief Financial Officer

Jefferies International Ltd: +44 (0)20 7029 8000

Simon Hardy

Harry Nicholas

Newgate Communications: +44 (0)20 7680 6550

Andrew Jones

Stephanie Dobbs

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.